Complex Drug-Device Generic Combination Products

Dr. . . .

DIA

October 9-10 Sheraton Silver Spring, MD

Facilitating Patient Access to High-Quality Generic Transdermal Products: The Role of FDA and GDUFA

Scientific Research, Development, and Regulatory Considerations for Complex Generic Transdermal Products

DIA-FDA Complex Drug-Device Generic Combination Products Meeting October 10, 2018 | Silver Spring, MD



The opinions and conclusions expressed in this forum are the viewpoints of the speaker(s) and do not necessarily reflect the official position of the U.S. Food and Drug Administration.

Equivalence for Generics

Pharmaceutical Equivalence (PE)

- Same active ingredient(s) and
- Same dosage form and
- Same route of administration and
- Same strength

Bioequivalence (BE)

- No significant differences in rate and extent of absorption at site of action
- Therapeutic Equivalence (TE) of Generic Products
 - PE + BE
 - Expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling



PE for TDS Products

- For Transdermal Delivery System (TDS) drug-device combination products, strength is not defined by drug load but by nominal drug delivery rate, and strengths are adjusted by size
- Compared to the Reference Listed Drug (RLD) product, a pharmaceutically equivalent TDS of the same strength may have a
 - Different drug load
 - Different "inactive" ingredients (including different adhesives)
 - Different dosage form design and formulation
 - Different product size and/or shape

Failure Modes for BE/TE

Failure to demonstrate BE may arise from:

- Differences in "inactive" ingredients
- Differences in dosage form design and formulation
- Differences in the drug load or size/shape of the TDS

These differences may have the potential to affect

- The rate and extent of drug delivery/absorption (BE)
- The adhesion of the TDS to the skin
- The irritation/sensitization potential of the TDS
- Other TDS product attributes
 - The control of drug delivery when exposed to heat (heat effects)
 - Transparency, size, metal content, etc.

Assessment of Prospective Generic TDS Products

- To ensure that generic TDS have the same rate and extent of absorption at the site of action, FDA recommends that applicants demonstrate BE, conducting key comparative product characterizations:
 - An in vivo comparative BE study with pharmacokinetic endpoints
 - An in vivo comparative adhesion study
 - An in vivo comparative irritation/sensitization study
 - An in vitro comparative heat effects study
- FDA routinely conducts and supports research to develop and/or revise scientific evidence-based regulatory standards.



The Regulatory Impact of Scientific Research

Case Study #1: Assessing Generic TDS Adhesion

- Optimization of the study design and control parameters
- Resolution of statistical analysis problems

Case Study #2: Assessing Generic TDS Heat Effects

- Development of methods to study TDS heat effects
- Demonstration of the clinical relevance of an in vitro approach

Regulatory Impact of Scientific Research

- Standardization of product development for all TDS products
- Reduction in study burden for industry
- Increase in availability of generic TDS




FIGURE SOURCE: https://en.wikipedia.org/wiki/Transdermal_patch (Free Media)



Assessing TDS adhesion (historically)


- Study designs varied across two dozen Product-Specific Guidances (PSGs)
- Results were difficult to interpret due to insufficient study controls
- Major issue with statistical analysis of non-inferiority for well-adhering TDS

Draft guidance for industry on assessing generic TDS adhesion

- Published June, 2016
- Introduced a new statistical analysis approach
- Revised criteria for primary and secondary endpoints
- Discussed numerous critical study controls, for example
 - Discouraged tampering with TDS
 - Discouraged restrictions on normal subject motion
 - Emphasized assessment of to-be-marketed TDS

New statistical analysis approach:

- Based upon a difference of means (DOM) instead of ratio of means (ROM)
- Margin of 0.15



Regulatory impact of scientific research

Among 40 TDS adhesion studies submitted in ANDAs

- 47.5% (19) consistently passed by both the old and new approaches
 - These had moderate or poor adhesion for the RLD
- 12.5% (5) consistently failed by both the old and new approaches
 - These had moderate or poor adhesion for the RLD
- 2.5% (1) passed the old approach, but failed NI by the new approach
 - This had poor adhesion for the RLD
- 37.5% (15) failed the old approach, but passed NI by the new approach
 - These had moderate or good adhesion for the RLD

Resulting in generics approved for fentanyl, rivastigmine & estradiol TDS



BREAKING NEWS! New and Revised TDS Guidances Posted

New and revised guidances for TDS products

27 harmonized, inter-related guidances posted in October of 2018, including:

- 1 revised draft guidance to evaluate TDS adhesion
- 1 new draft guidance to evaluate TDS *irritation/sensitization (I/S) potential*
- 2 *new PSGs* for TDS products
- 23 *revised PSGs* for TDS products

BREAKING NEWS! New and Revised TDS Guidances Posted

Revised draft guidance on evaluating adhesion

Draft Guidance for Industry on Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs includes:

- An option to use alternative scales & scoring approaches
- Numerous other clarifications and minor enhancements

New draft guidance on evaluating the I/S potential

Draft Guidance for Industry on Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs includes:

- An adoption of the DOM non-inferiority statistical approach (margin of 0.20)
- An option to use alternative scales and scoring approaches
- An option to not conduct a sensitization study in certain situations
- Numerous other clarifications and minor enhancements



Considerations for various scenarios of heat exposure:

- Early heat
- Late heat
- Continuous heat



FIGURE SOURCE: <u>http://www.clinicaladvisor.com/termsandconditions/</u> (Authorized non-commercial use) Inset image from the Ortho Evra® Prescribing Information (package insert)





FIGURE SOURCE: Ashburn et al. (2003) The Pharmacokinetics of Transdermal Fentanyl Delivered With and Without Controlled Heat. Journal of Pain Vol. 4, No 6: 291-297

Two different nicotine TDS products (PE but not BE)

Nicotine TDDS 14 mg/24h	Patch size (cm ²)	Rate/Area (μg/h/cm²)		Other inactive ingredients
Nicoderm CQ®	15.75	37	Polyisobutylene	Ethylene vinyl acetate-copolymer, polyethylene between pigmented and clear polyester backing
Aveva	20	29	Polyacrylate/Silicone	Polyester backing

Two different study designs for nicotine TDS heat exposure






In Vitro Permeation Test (IVPT) results reasonably predicted nicotine TDS heat effects in vivo


Approach I

(prediction based upon in vitro data only)



Approach II

(including an in vivo-derived heat factor)



REFERENCE: Shin, SH, et al. "In vitro-in vivo correlations for nicotine transdermal delivery systems evaluated by both in vitro skin permeation (IVPT) and in vivo serum pharmacokinetics under the influence of transient heat application." Journal of Controlled Release 270 (2018): 76-88. Page 17

12

Regulatory impact of scientific research

IVIVCs/IVIVRs were successfully developed for

- Different nicotine TDS
- Under both, normal and elevated skin surface temperature
- At different periods in the duration of product wear
- By independent research groups at different study sites
- Using different IVPT apparatus, skin preps & heat application methods
- Using different IVIVC approaches
- Illustrating an efficient in vitro approach to support the development of high quality, generic TDS products for patients



Conclusions

- TDS products are complex, and can exhibit unique issues relevant to demonstrating BE.
- Generic TDS products must be bioequivalent and therapeutically equivalent to the RLD.
- Generic TDS products may contain certain allowable design/formulation differences compared to the RLD TDS.
- Scientific research and innovation can streamline product development and reduce barriers/burdens for assessing BE.
- Collaboration among academia, industry and the FDA can facilitate patient access to high quality generic TDS products.

Special Acknowledgements



Dr. Wanjie Sun OTS/OB/DBVIII

Dr. Carol Kim OGD/OB/DCR

Dr. Priyanka Ghosh OGD/ORS/DTP

Dr. Tannaz Ramezanli OGD/ORS/DTP

Acknowledgements

Office of Generic Drugs (OGD) Center for Drug Evaluation & Research Research Collaborator

Office of Research & Standards

- Priyanka Ghosh, PhD
- Tannaz Ramezanli, PhD
- Bryan Newman, PhD
- Kaushalkumar Dave, PhD
- Yi Zhang, PhD
- Kimberly Witzmann, MD
- Markham Luke, MD, PhD
- Robert Lionberger, PhD

OGD (Other Offices)

- Carol Kim, PhD
- Daiva Shetty, MD
- Rong Wang, PhD
- Bing Li, PhD
- Andrew LeBoeuf, JD

- Wanjie Sun, PhD
- Stella Grosser, PhD
- Elena Rantou, PhD
- Jill Brown, BSN
- Bhagwant Rege, PhD
- Bing Cai, PhD
- Caroline Strasinger, PhD
- Andre Raw, PhD
- Lisa Soule, MD
- Dan Davis, MD
- Brenda Carr, MD
- Timothy Jiang, MD
- Irene Chan, PhD
- E. Dennis Bashaw, PharmD

Audra Stinchcomb, PhD University of Maryland, Baltimore

Funding

Funding for this work was made possible, in part, by the Food and Drug Administration through award U01FD004955. The views expressed in this presentation do not reflect the official policies of the U.S. Food and Drug Administration or the U.S. Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.



